References
Buckley, M. M., Brodgen, R. N., Barradell, L. B., Goa, K. L. Imipenem/cilastatin. Drugs 44 (1992) 408–444.
Extermann, M.: Traitement initial de sepsis: ceftazidime seule ou antibiothérapies combinées au choix du clinicien. Thèse no. 9450, Université de Genève, 1993.
Todd, P. A., Faulds, D. Ofloxacin. Drugs 42 (1991) 825–876.
Sanders, J. W., Powe, N. R., Moore, R. D. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J. Infect. Dis. 164 (1991) 907–916.
EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada — Clinical Trials Group Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J. Infect. Dis. 163 (1991) 951–958.
Rolston, K. V. I., Berkey, P., Bodey, G. P., Anaissie, E. J., Khardori, N. M., Joshi, J. H., Keating, M. J., Holmes, F. A., Cabanillas, F. F., Elting, L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch. Intern. Med. 152 (1992) 283–291.
Johnson, P. R., Liu Yin, J. A., Tooth, J. A. A randomized trial of high-dose ciprofloxacinversus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J. Antimicrob. Chemother. 30 (1992) 203–214.
Malik, I. A., Abbas, Z., Karim, M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339 (1992) 1092–1096.
Meunier, F., Zinner, H., Gaya, H., Calandra, T., Viscoli C., Klastersky, J., Glauser, M., andThe European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group Prospective randomised evaluation of ciprofloxacinversus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob. Agents Chemother. 35 (1991) 873–878.
Hoepelman, I. M., Rozenberg-Arska, M., Verhoef, J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet i (1988) 1305–1309.
Piccart, M., Klastersky, J., Meunier, F., Lagast, H., Van Laethem, Y., Weerts, D. Single-drugversus combination empirical therapy for gram-negative bacillary-infections in febrile cancer patients with and without granolocytopenia. Antimicrob. Agents Chemother. 26 (1984) 870–875.
Fainstein, V., Bodey, G. P., Elting, L., Bolivar, R., Keating, M. J., McCredie, K. B., Valdivieso, M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J. Antimicrob. Chemother. 12 Suppl. A (1983) 101–110.
Knaus, W. A., Draper, E. A., Wagner, D. P., Zimmerman, J. E. Apache II: A severity of disease classification system. Critic. Care Med. 13 (1985) 818–829.
Mouton, Y., Deboscker, Y., Bazin, C., Fourrier, F., Moulront, S., Philippon, A., Socolovsky, C., Suinat, J. L., Tondriaux, A. Etude prospective randomisée contrôlée imipénème-cilastatineversus céfotaxime-amikacine dans le traitement des infections respiratoires inférieures et des septicémies de réanimation. Presse Méd. 19 (1990) 607–612.
Poenaru, D., De Santis, M., Christou, N. V. Imipenem versus tobramycin-antianaerobe antibiotic therapy in intra-abdominal infections. Can. J. Surg. 33 (1990) 415–422.
Solomkin, J. S., Dellinger, E. P., Christou, N. V., Busuttil, R. W. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann. Surg. 212 (1990) 581–591.
Kalager, T., Andersen, B. M., Bergan, T., Brubakk, O., Bruun, J. N., Doskeland, B., Hellum, K. B., Hopen, G., Von der Lippe, E., Rahm, V., Ritland, S., Schreiner, A. Ciprofloxacinversus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scand. J. Infect. Dis. 24 (1992) 637–646.
Neu, H. C. New oral and parenteral quinolones. Am. J. Med. 87 Suppl. 5A (1989) 238S-287S.
Chow, J. W., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P., Ramphal, R., Wagener, M. M., Miyashiro, D. K., Yu, V. L. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115 (1991) 585–590.
Korvick, J. A., Bryan, C. S., Farber, B., Beam, T. R., Schenfeld, L., Muder, R. R., Weinbaum, D., Lumish, R., Gerding, D. N., Wagener, M. M., Yu, V. L. Prospective observational study of klebsiella bacteremia in 230 patients: outcome for antibiotic combinationsversus monotherapy. Antimicrob. Agents Chemother. 36 (1992) 2639–2644.
The EORTC International Antimicrobial Therapy Cooperative Group Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N. Engl. J. Med. 317 (1987) 1692–1698.
de Pauw, B. E., Pizzo, P. A., Verhagen, S., Novakova, I., Hathorn, J. W., Hiemenz, J., Browne, M., Commers, J., Cotton, D., Gress, J., Longo, D., Marshall, D., McKnight, J., Rubin, M., Skelton, J., Thaler, M., Wesley, R. “Antibiotic therapy in cancer patients with fever and neutropenia” (letters) N. Engl. J. Med. 316 (1987) 410–412.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Extermann, M., Regamey, C. Empirical antibiotic treatment of sepsis in non-neutropenic patients: Single agent or combination therapy?. Infection 22, 1–3 (1994). https://doi.org/10.1007/BF01780755
Issue Date:
DOI: https://doi.org/10.1007/BF01780755